Condition: Lupus Nephritis · Sponsor: Aurinia Pharmaceuticals Inc.
The goal of this clinical study is to assess the efficacy and safety of LUPKYNIS® in combination with belimumab, obinutuzumab or anifrolumab at inducing rapid renal response in patients with lupus nephritis (LN).
This description comes directly from the study's public registry record.
Aurinia Clinical Trials Information · 833-606-5975 · clinicaltrials@auriniapharma.com
Always discuss trial participation with your own doctor first.
| Purushotham & Akther Kotha MD, Inc. | La Mesa, California, United States | Recruiting |
| Valerius Medical Group & Research Center of Greater Long Beach, Inc. | Los Alamitos, California, United States | Recruiting |
| Swati Shah MD Rheumatology, LLC | Jacksonville, Florida, United States | Recruiting |
| CTR Oakwater | Orlando, Florida, United States | Recruiting |
| Parris and Associates Rheumatology | Lawrenceville, Georgia, United States | Recruiting |
| Accurate Clinical Research, Inc. | Lake Charles, Louisiana, United States | Recruiting |
| Arthritis and Osteoporosis Consultants of the Carolinas | Charlotte, North Carolina, United States | Recruiting |
| Joint and Muscle Research Institute | Charlotte, North Carolina, United States | Recruiting |
| West Tennessee Research Institute | Jackson, Tennessee, United States | Recruiting |
| Novel Research LLC | Bellaire, Texas, United States | Recruiting |
| Liberty Research Center | Dallas, Texas, United States | Recruiting |
| Integrative Rheumatology of South Texas | Harlingen, Texas, United States | Recruiting |
+ 3 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07611214